CN104491194A - Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine - Google Patents

Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine Download PDF

Info

Publication number
CN104491194A
CN104491194A CN201410732601.1A CN201410732601A CN104491194A CN 104491194 A CN104491194 A CN 104491194A CN 201410732601 A CN201410732601 A CN 201410732601A CN 104491194 A CN104491194 A CN 104491194A
Authority
CN
China
Prior art keywords
weight portion
radix
medicine
heart disease
blocking type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410732601.1A
Other languages
Chinese (zh)
Inventor
肖玉翠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410732601.1A priority Critical patent/CN104491194A/en
Publication of CN104491194A publication Critical patent/CN104491194A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/264—Aristolochia (Dutchman's pipe)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine for treating the cardiopulmonary stasis blocking type rheumatic heart disease and a preparation method of the medicine. The medicine is prepared from the following raw material medicines: cynachum uilfordii hemsl, negundo chastetree fruits, trogopterus dung, peach kernels, carthamus tinctorius, ligusticum wallichii, angelica sinensis, radix paeoniae rubra, rehmannia, radix bupleuri, kadsura heteroclite, eriosema himalaicum, herba aristolochiae and liquorice. The medicine has the beneficial effects that the medicine has the main effects of removing dampness and eliminating phlegm, promoting blood circulation to remove blood stasis and promoting qi circulation to relieve pain, has the auxiliary effects of benefiting qi for activating blood circulation, tranquilizing by nourishing the heart, invigorating stomach and tonifying the spleen, can treat both the symptoms and the root causes of the cardiopulmonary stasis blocking type rheumatic heart disease, not only has the advantages of good treatment effect, no tonic or side effect and small pain, but also can be used for improving the living quality of patients and improving the organism immunity, and has a long-lasting anti-recidivity effect.

Description

Be used for the treatment of medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease and preparation method thereof
Technical field
The present invention relates to pharmaceutical technology, particularly relate to and be a kind ofly used for the treatment of medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease and preparation method thereof.
Background technology
Rheumatic heart disease is called for short rheumatic heart disease, refers to due to rheumatic fever activity, involves cardiac valve and the valve disorder that causes.Show as in Bicuspid valve, Tricuspid valve, aortic valve and have one or several valvular stenosis and (or) incompetence.Narrow or incompetence often exists simultaneously clinically, but normal based on one.Usually non-evident sympton of ill initial stage, stage shows as palpitation and short breath, weak, cough, lower limbs edema, cough the cardiac function such as pink foam expectorant loses compensatory performance.Primary disease is mainly in winter-spring season, under cold, humidity and crowded environment.
Rheumatic heart disease is that first group beta hemolytic streptococcus infects the allergic part performance caused, and belongs to autoimmune disease.The pathological change of cardia mainly occurs in cardiac valve position.Bicuspid valve is the most common affected area.
Due to valvular pathological changes, heart is gone wrong in hemophoric process, as valvular stenosis, resistance of blood flow is strengthened, and in order to penetrate enough blood, heart is diastole and contraction more arduously then, heart working intensity is made to strengthen like this, efficiency reduces, and heart fatiguability, causes cardiac hypertrophy in the course of time.As mitral stenosis to a certain extent time increasing due to left atrial pressure, cause pulmonary vein and pulmonary capillary pressure to increase, formed pulmonary venous pleonaemia, easily cause following symptom after pulmonary venous pleonaemia: 1. dyspnea; 2. cough; 3. hemoptysis, what have also there will be hoarseness and dysphagia.
Traditional Chinese medical science Traditional Chinese Medicine is thought, their early stage invades caused by human body for the damp and hot poison of wind and cold mostly, stays in joint, interiorly gives up in the heart; Mid-term visible blockage of the cardiac vessels, the phenomenon such as smooth, the stagnation of QI and blood may bring about pain of blood fortune; Late period deficiency of YIN affecting YANG, deficiency in both YIN and YANG, phlegm and blood stasis, diseases caused by retention of fluid stagnate, and occurs that even empty sun is for de-, finally jeopardizes sufferer life.Clinically, Chinese medical discrimination rheumatic heart disease is often divided into following four types: cardiopulmonary stasis blocking person, lack of preservation of spirit, deficiency of qi and blood person, heart deficiency of spleen-YANG holds stasis of blood person under the arm, all void of heart spleen kidney yang holds stasis of blood person under the arm, wherein the common shortness of breath and palpitation of cardiopulmonary blood stasis blocking type, chest pain are felt oppressed, hemoptysis of coughing up phlegm, two cheekbones are purplish red, some patient is dark, the purple lip of the face stasis of blood even, and its body of the tongue stasis of blood is dark or have petechia.
At present, doctor trained in Western medicine is asymptomatic Patients With Rheumatic Valvular Disease to chronic rheumatic valvulopathy, general needs performs the operation, there is symptom and belong to Operation indication person, can select to make mitral commissurotomy or prosthetic valve replacement, prosthetic valve replacement is the main method that the aortic valve for the treatment of rheumatic heart disease is narrow.Western medicine method common medicine has sorbitrate, nifedipine, atenolol, trimetazidine etc.Antibiotic choosing kills streptococcus, antibiotic that sensitivity is high, penicillin 4,000,000-800 ten thousand u, VD, 1 time/d, continuous 10-14d, then uses 800,000 u, im, 2 times/d.When ASO is normal, change durative action preparation benzathine benzylpenicillin 1,200,000 u into, im, 1 time/d.Salicylic Acid Formulations: select enteric coated aspirin 4-6g/d, divides and immediately takes after meal for 3-4 time, to alleviate gastrointestinal symptom, take gel aluminum hydroxide if desired, serve on 3-6 month, decrement 2g/d, adrenocortical hormone: can hydrocortisone 100mg+100ml liquid be used, VD, 1 time/d when there is high heat, body temperature uses prednisone 30-40mg instead after controlling, 1 time/morning, oral, decrement after 2 weeks, every 3d subtracts 2.5mg, until 5mg, continuously with rear drug withdrawal in 8 weeks.Although western medicine has certain therapeutic effect, there is untoward reaction and can increase the weight of the state of an illness or cause new disease to occur, to ARR treatment pros and cons half and half, small number of patients adopts operative treatment, but operative treatment needs long-term anticoagulation to treat, and risk is larger.
Summary of the invention
Technical problem to be solved by this invention is, there is provided a kind of and be used for the treatment of medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease and preparation method thereof, treating both the principal and the secondary aspects of a disease at the same time, not only have therapeutic effect good, have no side effect, the painful advantage such as little, and can also Quality of Life of Patients be improved, enhancing human body immunity power, has the effect of lasting anti-recurrence.
In order to solve the problems of the technologies described above, the invention provides a kind of medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease, described medicine comprises following raw medicinal material: Radix cynanchi wilfordii, Fructus Viticis Negundo, Oletum Trogopterori, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Rehmanniae, Radix Bupleuri, Radix seu Caulis Kadsurae Heteroclitae, Eriosema himalaicum Ohashi, Herba Aristolochiae and Radix Glycyrrhizae.
Described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 15-25 weight portion, Fructus Viticis Negundo 12-20 weight portion, Oletum Trogopterori 15-20 weight portion, Semen Persicae 10-20 weight portion, Flos Carthami 10-20 weight portion, Rhizoma Chuanxiong 10-20 weight portion, Radix Angelicae Sinensis 12-20 weight portion, Radix Paeoniae Rubra 8-16 weight portion, Radix Rehmanniae 10-17 weight portion, Radix Bupleuri 5-12 weight portion, Radix seu Caulis Kadsurae Heteroclitae 7-15 weight portion, Eriosema himalaicum Ohashi 10-20 weight portion, Herba Aristolochiae 8-20 weight portion and Radix Glycyrrhizae 10-20 weight portion.
Described medicine is preferably made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion and Radix Glycyrrhizae 15 weight portion.
Described medicine also comprises Radix Salviae Miltiorrhizae, Fructus Jujubae, Herba menyanthis and Caulis Polygoni Multiflori.
Described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 15-25 weight portion, Fructus Viticis Negundo 12-20 weight portion, Oletum Trogopterori 15-20 weight portion, Semen Persicae 10-20 weight portion, Flos Carthami 10-20 weight portion, Rhizoma Chuanxiong 10-20 weight portion, Radix Angelicae Sinensis 12-20 weight portion, Radix Paeoniae Rubra 8-16 weight portion, Radix Rehmanniae 10-17 weight portion, Radix Bupleuri 5-12 weight portion, Radix seu Caulis Kadsurae Heteroclitae 7-15 weight portion, Eriosema himalaicum Ohashi 10-20 weight portion, Herba Aristolochiae 8-20 weight portion, Radix Salviae Miltiorrhizae 15-25 weight portion, Fructus Jujubae 10-18 weight portion, Herba menyanthis 12-20 weight portion, Caulis Polygoni Multiflori 10-15 weight portion and Radix Glycyrrhizae 10-22 weight portion.
Described medicine is preferably made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion, Radix Salviae Miltiorrhizae 20 weight portion, Fructus Jujubae 15 weight portion, Herba menyanthis 16 weight portion, Caulis Polygoni Multiflori 13 weight portion and Radix Glycyrrhizae 15 weight portion.
In order to better realize foregoing invention object, the invention provides a kind of preparation method being used for the treatment of the medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease, when the dosage form of described medicine is drop pill, described preparation method is:
(1) take the mixing of all raw medicinal materials by weight, decoct with water 2 ~ 4 times, each 1 ~ 3 hour, add the water of 6 ~ 10 times amount, decoction liquor is filtered, and merges the filtrate of each time at every turn, concentrated, crushed after being dried, then add determining alcohol be 90% ~ 95% ethanol to alcohol content be 40% ~ 50%, leave standstill 3 ~ 5 hours, filter, filtrate is condensed into extractum, adds extractum 0.5-1 water doubly, leave standstill after stirring, filter, precipitate cold drying is also pulverized, and sieve acquisition mixed-powder;
(2) getting mixed-powder in step (1) puts in the substrate of 2-4 times amount melting, and mixing, in instillation coolant, obtains drop pill.
Described substrate is one or more in sodium stearate, glycerin gelatine, stearic acid, glyceryl monostearate, hydrogenated vegetable oil or insect wax.
When the dosage form of described medicine is granule, described preparation method is:
Step one: described raw medicinal material is mixed in described ratio, adding relative to the determining alcohol of 4 ~ 8 times, mixture is the ethanol of 85% ~ 95%, be heated to boiling reflux 3 ~ 5 hours, filter, adopt percolation with the speed of 1 ~ 2ml per minute slowly percolation, collect percolate, when being evaporated to 50 ~ 60 DEG C subsequently under vacuum 0.06 ~ 0.09Mpa, relative density is the mastic of 1.04 ~ 1.10, spraying dry, the inlet temperature 160 ~ 175 DEG C of spray dryer, leaving air temp 80 ~ 85 DEG C, be ground into powder subsequently, make dried cream powder;
Step 2: the dextrin adding cane sugar powder relative to dried cream powder quality 0.2 ~ 0.4 times and 0.1 ~ 0.2 times in the dried cream powder obtained, makes granule, in 40 ~ 50 DEG C of dryings, obtains granule.
The invention has the beneficial effects as follows: medicine of the present invention is based on dampness removing expectorant, blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, be auxiliary with benefiting QI for activating blood circulation, tranquilizing by nourishing the heart, stomach invigorating spleen reinforcing, treatment cardiopulmonary blood stasis blocking type rheumatic heart disease, treating both the principal and the secondary aspects of a disease at the same time, not only have therapeutic effect good, have no side effect, the painful advantage such as little, and can also Quality of Life of Patients be improved, enhancing human body immunity power, there is the effect of lasting anti-recurrence.
Detailed description of the invention
The invention provides a kind of medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease, comprise Radix cynanchi wilfordii, Fructus Viticis Negundo, Oletum Trogopterori, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Rehmanniae, Radix Bupleuri, Radix seu Caulis Kadsurae Heteroclitae, Eriosema himalaicum Ohashi, Herba Aristolochiae and Radix Glycyrrhizae, preferably medicine also comprises Radix Salviae Miltiorrhizae, Fructus Jujubae, Herba menyanthis and Caulis Polygoni Multiflori.With Radix cynanchi wilfordii, Fructus Viticis Negundo, the expectorant of Oletum Trogopterori dampness removing in side, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling are principal agent, Radix Angelicae Sinensis, Radix Paeoniae Rubra nourshing blood and promoting blood circulation, and two medicines help principal agent to take blood circulation promoting and blood stasis dispelling as accessory drugs; Radix Rehmanniae joins Chinese Angelica blood replonishing and blood, makes blood stasis dispelling and non-impairment of YIN blood, the stagnation of QI in Radix Bupleuri, Radix seu Caulis Kadsurae Heteroclitae, Eriosema himalaicum Ohashi, Herba Aristolochiae, Radix cynanchi wilfordii the chest stuffiness relieving; circulation of qi promoting pain relieving; Radix Salviae Miltiorrhizae, Fructus Jujubae benefiting QI for activating blood circulation, Herba menyanthis, Caulis Polygoni Multiflori tranquilizing by nourishing the heart, Herba menyanthis, Eriosema himalaicum Ohashi stomach invigorating spleen reinforcing be adjuvant drug in the side of being altogether; Radix Glycyrrhizae coordinates all medicines for making, and closes and with it, makes all diseases of cardiopulmonary blood stasis blocking type rheumatic heart disease more.
Wherein, the pharmacology of above-mentioned raw materials medical material is as follows:
Radix cynanchi wilfordii: sweet in the mouth; Micro-hardship; Slightly warm in nature; Return spleen; Stomach; Kidney channel.Function cures mainly: yin nourishing tonify deficiency, strengthening the spleen to promote digestion.Control deficient impairment caused by overstrain, dysentery, infantile malnutrition, have a stomachache glutted, leucorrhea, skin ulcer tinea.1. " detailed outline ": " main abdominal distention stagnates." 2. " vegetation is side just ": " vinegar mill is coated with tinea." 3. " classifying herbal ": " helps digestion long-pending, and stimulating milk secretion, tonify deficiency is weak.Sore, lymphogranuloma inguinale are controlled in " 4. " Guizhou side's medicine among the people collection ": " external." 5. " Shaanxi Chinese herbal medicine ": " nourishing YIN and benefiting blood, spleen invigorating is pleasant, sedation-analgesia, lactogenic.To treat for stomachache abdominal distention, asthenia, lumbago due to renal deficiency, sexual impotence, the abdominal lump of chilren, leucorrhea, hypogalactia." 6. " south mainly contains poisonous plant ": " controls oedema due to nephritis, gastric and duodenal ulcers." 7. " Jiangxi medical herbs ": " heat-clearing and toxic substances removing, pleasant dysentery relieving."
Fructus Viticis Negundo: acrid in the mouth; Bitter; Warm in nature.Return lung; Stomach; Liver Channel.Function cures mainly: expelling pathogenic wind from the body surface, relieving cough and asthma; To regulate the flow of vital energy the pain relieving that helps digestion.Main Common Cold; Cough; Asthma; Stomachache acid regurgitation; Dyspepsia; Food stagnation dysentery; Cholecystitis, cholelithiasis; Hernia.
Oletum Trogopterori: sweet, temperature.Function cures mainly: promoting blood circulation to remove blood stasis, and parch to black stops blooding.Have a pain for trusted subordinate's congestion, dysmenorrhea, blood stasis amenorrhea, puerperal abdominalgia with blood stasis; Parch to black controls metrostaxis; Traumatic injury is controlled in external, Serpentis, insect bite wound.
Semen Persicae: bitter, sweet, flat.GUIXIN, liver, large intestine channel.Function cures mainly: blood circulation promoting and blood stasis dispelling, loosening bowel to relieve constipation.For amenorrhea, dysmenorrhea ， WEIJIA mass in the abdomen, injury from falling down, dryness of the intestine constipation.
Flos Carthami: pungent, temperature.GUIXIN, Liver Channel.Function cures mainly: promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.For amenorrhea, dysmenorrhea, lochia, lump in the abdomen mass in the abdomen, injury from falling down, skin infection swells and ache.
Rhizoma Chuanxiong: pungent, temperature.Return liver, gallbladder, pericardium channel.Function cures mainly: blood-activating and qi-promoting, wind-expelling pain-stopping.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia.
Radix Angelicae Sinensis: sweet, acrid, warm.Return liver, the heart, spleen channel.Function cures mainly: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.For blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.Radix Angelicae Sinensis (processed with wine) promoting blood circulation to restore menstrual flow.For amenorrhea dysmenorrhea, rheumatic arthralgia, injury from falling down.
Radix Paeoniae Rubra: bitter, is slightly cold.Return Liver Channel.Function cures mainly: clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, hematemesis and epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, injury from falling down, carbuncle skin infection.
Radix Rehmanniae: Radix Rehmanniae: sweet, bitter, cold.Radix Rehmanniae: sweet, cold.GUIXIN, liver, kidney channel.Function cures mainly: Radix Rehmanniae: clearing away heat and promoting production of body fluid, removing heat from blood, hemostasis.For consumption of YIN caused by febrile disease, crimson tongue excessive thirst, sends out speckle dermexanthesis, spits blood, epistaxis, laryngopharynx swelling and pain.Radix Rehmanniae: clearing away heat and cooling blood, yin nourishing, promotes the production of body fluid.For calentura crimson tongue excessive thirst, yin asthenia generating intrinsic heat, hectic fever due to YIN-deficiency consumptive fever, interior-heat is quenched one's thirst, and spits blood, and epistaxis sends out speckle dermexanthesis.The Radix Rehmanniae that the present invention uses.
Radix Bupleuri: bitter, is slightly cold.Return liver, gallbladder meridian.Function cures mainly: reconciling superficies and interior, soothing the liver, yang invigorating.For cold, fever, alternate attack of chill and fever, distending pain in the chest and hypochondrium, menoxenia, sub-official's prolapsus, proctoptosis.
Radix seu Caulis Kadsurae Heteroclitae: pungent; Bitter; Warm in nature.Return spleen; Stomach; Liver Channel.Function cures mainly: expelling wind and removing dampness; Promoting the circulation of QI to relieve pain; Relaxing muscles and tendons and activating QI and blood in the collateral.Main air pain of dampness syndrome; Stomachache; Stomachache; Dysmenorrhea; Puerperal abdonimal pain; Traumatic injury; Chronic lambago and skelalgia.
Eriosema himalaicum Ohashi: sweet, bitter, puckery is flat.Function cures mainly: stomach invigorating removing food stagnancy, regulating QI to relieve pain.For infantile malnutrition, dyspepsia, stomach abdomen pain, diarrhoea, traumatic injury.
Herba Aristolochiae: bitter, temperature.Return liver,spleen,kidney warp.Function cures mainly: promoting flow of QI and blood, inducing diuresis to remove edema.For gastral cavity ventral spine pain, arthralgia, edema during pregnancy.
Radix Glycyrrhizae: sweet, flat.GUIXIN, lung, spleen, stomach warp.Function cures mainly: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the anxious pain of gastral cavity abdomen, extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Radix Salviae Miltiorrhizae: bitter, is slightly cold.GUIXIN, Liver Channel.Function cures mainly: stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, and clear away heart-fire relieving restlessness.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.
Fructus Jujubae: sweet, temperature.Return spleen, stomach warp.Function cures mainly: invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind.For insufficiency of the spleen lack of appetite, weak loose stool, woman hysteria.
Herba menyanthis: sweet, bitter, cold.Function cures mainly: clearing away heat and promoting diuresis, and stomach invigorating is calmed the nerves.For gastritis, dyspepsia, cholecystitis, jaundice, hypertension, cardiopalmus, insomnia.
Caulis Polygoni Multiflori: sweet is flat.GUIXIN, Liver Channel.Function cures mainly: nourishing blood to tranquillize the mind, dispelling wind and removing obstruction in the collateral.For insomnia and dreamful sleep, blood deficiency general pain, rheumatic arthralgia; External treatment skin pruritus.
Below adopt embodiment to describe embodiments of the present invention in detail, to the present invention, how application technology means solve technical problem whereby, and the implementation procedure reaching technique effect can fully understand and implement according to this.
Embodiment 1 granule
Embodiments provide a kind of medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease, be made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion and Radix Glycyrrhizae 15 weight portion.
Its preparation method is:
Step one: described raw medicinal material is mixed in described ratio, adding relative to the determining alcohol of 6 times, mixture is the ethanol of 90%, be heated to boiling reflux 4 hours, filter, adopt percolation with the speed of 2ml per minute slowly percolation, collect percolate, when being evaporated to 55 DEG C subsequently under vacuum 0.07Mpa, relative density is the mastic of 1.08, spraying dry, the inlet temperature 170 DEG C of spray dryer, leaving air temp 80 DEG C, be ground into powder subsequently, make dried cream powder;
Step 2: the dextrin adding cane sugar powder relative to dried cream powder quality 0.3 times and 0.1 times in the dried cream powder obtained, makes granule, in 45 DEG C of dryings, obtains granule.
Embodiment 2 drop pill
Embodiments provide a kind of medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease, be made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion, Radix Salviae Miltiorrhizae 20 weight portion, Fructus Jujubae 15 weight portion, Herba menyanthis 16 weight portion, Caulis Polygoni Multiflori 13 weight portion and Radix Glycyrrhizae 15 weight portion.
Its preparation method is:
(1) take the mixing of all raw medicinal materials by weight, decoct with water 3 times, each 2 hours, add the water of 8 times amount, decoction liquor is filtered, and merges the filtrate of each time at every turn, concentrated, crushed after being dried, then add determining alcohol be 90% ~ 95% ethanol to alcohol content be 45%, leave standstill 4 hours, filter, filtrate is condensed into extractum, adds the water of extractum 0.8 times, leave standstill after stirring, filter, precipitate cold drying is also pulverized, and sieve acquisition mixed-powder;
(2) getting mixed-powder in step (1) puts in the substrate of 3 times amount meltings, and mixing, in instillation coolant, obtains drop pill; Wherein, sodium stearate and the glyceryl monostearate of substrate to be ratio of weight and number be 1:2.
Toxicity test
With the granule of the embodiment of the present invention 1 for object, give white mouse large enteral dispensing, observe 7 for 150 times of clinical consumption per day.The all animals of result are strong deposits, and its activity, diet, hair, Excreta are no abnormal, have no toxic reaction.Irritation test is carried out to white mouse vagina and damaged skin, there are no irritative response and other untoward reaction.Toxicity test proves, the not toxic effect of this medicine and untoward reaction, clinical practice is safe and reliable
The drop pill of the embodiment of the present invention 2 is pressed 7.81,18.34 and 40.11g crude drug/kg continuous use 12 weeks (1.0ml/100g body weight to mice, every day 2 times) and drug withdrawal after 4 weeks, result shows: the index such as hair, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat of Chinese medicine preparation of the present invention to mice all has no significant effect, internal organs naked eyes do not find that difference change and histological indications show, medication 12 weeks and drug withdrawal are after 4 weeks, and Organs of Mice is all without obviously changing.Illustrate that Chinese medicine preparation of the present invention is little to toxicity after mice long-term prescription, also there is no difference reaction after drug withdrawal, application safety.
Select 20 healthy mices, female, each 10 of hero, with the drop pill of the embodiment of the present invention 2 for object, dose design is first phase in every 5 days, each issue dosage is respectively 0.10LD50,0.15LD50,0.22LD50,0.34LD 50,0.50LD50, the LD 50 that is female, male mice of this sample be 5000m part/k part BW (five dosage is 500,750,1100,1700,2500m part/k part BW).Within every 5 days, weigh once, adjustment dosage, by 0.1ml/10 part BW per os gavage.After 20 days, animal occurs without death condition, off-test, and by ascending-dose to tested material after 20 days, female, buck all occurs without death condition.
Clinical trial
Select 270 examples from the patient of the court's Cardiological, all cases all meet the diagnostic criteria of rheumatic heart disease, and make a definite diagnosis and belong to cardiopulmonary blood stasis blocking type.Man 120 example, female 150 example, average 49.8 years old, 270 routine patients are divided into three groups by the course of disease 11.2 ± 6.3 years at random, often organize 90 examples, be respectively embodiment group 1, embodiment group 2 and matched group, respectively organize all no difference of science of statistics such as patient age, sex, the state of an illness, there is comparability.
Diagnostic criteria:
With reference to formulations such as China Association of Traditional Chinese Medicine " tcm internal medicine commonly encountered diseases clinic diagnosis guide " (ZYYXH/T121-2008), " modern Chinese medicine angiocardiology " (People's Health Publisher's version in 2006) " Chinese medical disease Standardization of diagnosis and curative effect " (nineteen ninety-five People's Republic of China's traditional Chinese medicine industry standards).
Cardinal symptom: uncomfortable in chest, breathe hard, weak, very then there is dyspnea;
Minor symptom: nervous, spitting of blood, cough, edema, cyanosis etc.
According to above symptom in conjunction with 2-dimensional echocardiography and diagnosable.
Hope according to the traditional Chinese medical science, hear, ask, cut and be dialectically diagnosed as cardiopulmonary blood stasis blocking type rheumatic heart disease further.
Therapeutic Method:
Embodiment group 1: the granule using the embodiment of the present invention 1, every day three times, each 12g, every 10 days is a course for the treatment of, treats 3-8 the course for the treatment of continuously;
Embodiment group 2: the drop pill using the embodiment of the present invention 2, every day three times, each 10 balls, every 10 days is a course for the treatment of, treats 3-8 the course for the treatment of continuously;
Matched group: use trimetazidine, every day three times, each 20mg, every 10 days is a course for the treatment of, treats 3-8 the course for the treatment of continuously.
Criterion of therapeutical effect: recovery from illness: sings and symptoms all disappears, functional activity recovers normal, can be competent at routine work and housework; Effective: symptomatology or cardinal symptom are eliminated, and the progress to some extent of clinical symptoms and sign, can participate in slight physical exertion; Invalid: compare each side all without progressive early stage with treatment, symptom and sign are all unchanged or increase the weight of, even dead.
Therapeutic outcome:
See table 1 and table 2, as can be seen from Table 1, adopt Drug therapy cardiopulmonary blood stasis blocking type rheumatic heart disease of the present invention, relative to conventional medicament on therapeutic effect, there is significant improvement; As can be seen from Table 2, adopt Drug therapy cardiopulmonary blood stasis blocking type rheumatic heart disease of the present invention, relative to conventional medicament, treatment the course for the treatment of on significantly shorten.
After table 1 three components does not treat 3 courses for the treatment of, Clinical efficacy comparison is routine
Group Number of cases Cure Effectively Invalid Cure rate Total effective rate
Embodiment group 1 90 78 10 2 86.7% 97.8%
Embodiment group 2 90 83 7 0 92.2% 100%
Matched group 90 46 27 17 51.1% 81.1%
Table 2 three components does not treat healing number and time comparative example (%) after 3-8 the course for the treatment of
Group Number of cases 3-4 the course for the treatment of 5-6 the course for the treatment of 7-8 the course for the treatment of
Embodiment group 1 78 37(47.4%) 35(44.9%) 6(7.7%)
Embodiment group 2 83 41(49.4%) 35(42.2%) 7(8.4%)
Matched group 46 9(19.6%) 18(39.1%) 19(41.3%)
According to the clinical statistics in above table, medicine provided by the invention have rapid-action, effective percentage is high, safety is high, the advantage that has no side effect; Simultaneously to each group of recovery from illness follow-up of patients 1 year, result is added up, and in embodiment group 1,78 example recoveries from illness have 1 example recurrence, and relapse rate is 1.3%, 83 routine patients 1 example recurrences in embodiment group 2, and relapse rate is 1.2%, and 46 routine Patients on Recurrences 9 examples in matched group, relapse rate is 19.6%.
Model case
Zhang, female, 31 years old, suffer from the rheumatic heart disease several years, initial stage non-evident sympton, continue to occur after 2-3 palpitation and short breath, weak, cough, cough the cardiac function such as pink foam expectorant and lose compensatory performance, come to go to a doctor in January, 2013, according to symptom and in conjunction with 2-dimensional echocardiography, be diagnosed as cardiopulmonary blood stasis blocking type rheumatic heart disease, use the drop pill of the embodiment of the present invention 2 to treat, every day three times, each 10 balls, every 10 days is a course for the treatment of, and treat 3 courses for the treatment of continuously, symptom is clearly better, fully recover after continuing to take 2 courses for the treatment of, follow up a case by regular visits to and do not recur for 1 year.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.

Claims (9)

1. be used for the treatment of the medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease, it is characterized in that, described medicine comprises following raw medicinal material: Radix cynanchi wilfordii, Fructus Viticis Negundo, Oletum Trogopterori, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Rehmanniae, Radix Bupleuri, Radix seu Caulis Kadsurae Heteroclitae, Eriosema himalaicum Ohashi, Herba Aristolochiae and Radix Glycyrrhizae.
2. the medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease according to claim 1, it is characterized in that, described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 15-25 weight portion, Fructus Viticis Negundo 12-20 weight portion, Oletum Trogopterori 15-20 weight portion, Semen Persicae 10-20 weight portion, Flos Carthami 10-20 weight portion, Rhizoma Chuanxiong 10-20 weight portion, Radix Angelicae Sinensis 12-20 weight portion, Radix Paeoniae Rubra 8-16 weight portion, Radix Rehmanniae 10-17 weight portion, Radix Bupleuri 5-12 weight portion, Radix seu Caulis Kadsurae Heteroclitae 7-15 weight portion, Eriosema himalaicum Ohashi 10-20 weight portion, Herba Aristolochiae 8-20 weight portion and Radix Glycyrrhizae 10-20 weight portion.
3. the medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease according to claim 1 and 2, it is characterized in that, described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion and Radix Glycyrrhizae 15 weight portion.
4. the medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease according to any one of claim 1-3, is characterized in that, described medicine also comprises Radix Salviae Miltiorrhizae, Fructus Jujubae, Herba menyanthis and Caulis Polygoni Multiflori.
5. the medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease according to any one of claim 1-4, it is characterized in that, described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 15-25 weight portion, Fructus Viticis Negundo 12-20 weight portion, Oletum Trogopterori 15-20 weight portion, Semen Persicae 10-20 weight portion, Flos Carthami 10-20 weight portion, Rhizoma Chuanxiong 10-20 weight portion, Radix Angelicae Sinensis 12-20 weight portion, Radix Paeoniae Rubra 8-16 weight portion, Radix Rehmanniae 10-17 weight portion, Radix Bupleuri 5-12 weight portion, Radix seu Caulis Kadsurae Heteroclitae 7-15 weight portion, Eriosema himalaicum Ohashi 10-20 weight portion, Herba Aristolochiae 8-20 weight portion, Radix Salviae Miltiorrhizae 15-25 weight portion, Fructus Jujubae 10-18 weight portion, Herba menyanthis 12-20 weight portion, Caulis Polygoni Multiflori 10-15 weight portion and Radix Glycyrrhizae 10-22 weight portion.
6. the medicine being used for the treatment of cardiopulmonary blood stasis blocking type rheumatic heart disease according to any one of claim 1-5, it is characterized in that, described medicine is made up of the raw medicinal material of following parts by weight: Radix cynanchi wilfordii 21 weight portion, Fructus Viticis Negundo 16 weight portion, Oletum Trogopterori 17 weight portion, Semen Persicae 15 weight portion, Flos Carthami 15 weight portion, Rhizoma Chuanxiong 15 weight portion, Radix Angelicae Sinensis 16 weight portion, Radix Paeoniae Rubra 12 weight portion, Radix Rehmanniae 13 weight portion, Radix Bupleuri 8 weight portion, Radix seu Caulis Kadsurae Heteroclitae 11 weight portion, Eriosema himalaicum Ohashi 15 weight portion, Herba Aristolochiae 14 weight portion, Radix Salviae Miltiorrhizae 20 weight portion, Fructus Jujubae 15 weight portion, Herba menyanthis 16 weight portion, Caulis Polygoni Multiflori 13 weight portion and Radix Glycyrrhizae 15 weight portion.
7. the preparation method being used for the treatment of the medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease according to any one of claim 1-6, is characterized in that, the dosage form of described medicine is drop pill, and described preparation method is:
(1) take the mixing of all raw medicinal materials by weight, decoct with water 2 ~ 4 times, each 1 ~ 3 hour, add the water of 6 ~ 10 times amount, decoction liquor is filtered, and merges the filtrate of each time at every turn, concentrated, crushed after being dried, then add determining alcohol be 90% ~ 95% ethanol to alcohol content be 40% ~ 50%, leave standstill 3 ~ 5 hours, filter, filtrate is condensed into extractum, adds extractum 0.5-1 water doubly, leave standstill after stirring, filter, precipitate cold drying is also pulverized, and sieve acquisition mixed-powder;
(2) getting mixed-powder in step (1) puts in the substrate of 2-4 times amount melting, and mixing, in instillation coolant, obtains drop pill.
8. the preparation method being used for the treatment of the medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease according to claim 7, it is characterized in that, described substrate is one or more in sodium stearate, glycerin gelatine, stearic acid, glyceryl monostearate, hydrogenated vegetable oil or insect wax.
9. the preparation method being used for the treatment of the medicine of cardiopulmonary blood stasis blocking type rheumatic heart disease according to any one of claim 1-6, is characterized in that, the dosage form of described medicine is granule, and described preparation method is:
Step one: described raw medicinal material is mixed in described ratio, adding relative to the determining alcohol of 4 ~ 8 times, mixture is the ethanol of 85% ~ 95%, be heated to boiling reflux 3 ~ 5 hours, filter, adopt percolation with the speed of 1 ~ 2ml per minute slowly percolation, collect percolate, when being evaporated to 50 ~ 60 DEG C subsequently under vacuum 0.06 ~ 0.09Mpa, relative density is the mastic of 1.04 ~ 1.10, spraying dry, the inlet temperature 160 ~ 175 DEG C of spray dryer, leaving air temp 80 ~ 85 DEG C, be ground into powder subsequently, make dried cream powder;
Step 2: the dextrin adding cane sugar powder relative to dried cream powder quality 0.2 ~ 0.4 times and 0.1 ~ 0.2 times in the dried cream powder obtained, makes granule, in 40 ~ 50 DEG C of dryings, obtains granule.
CN201410732601.1A 2014-12-07 2014-12-07 Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine Pending CN104491194A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410732601.1A CN104491194A (en) 2014-12-07 2014-12-07 Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410732601.1A CN104491194A (en) 2014-12-07 2014-12-07 Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine

Publications (1)

Publication Number Publication Date
CN104491194A true CN104491194A (en) 2015-04-08

Family

ID=52932708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410732601.1A Pending CN104491194A (en) 2014-12-07 2014-12-07 Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine

Country Status (1)

Country Link
CN (1) CN104491194A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961928A (en) * 2005-11-10 2007-05-16 杨文龙 Blood circulation-activating stasis-removing medicament for treating blood stasis syndrome and preparation process thereof
CN101229267A (en) * 2008-01-14 2008-07-30 北京中科雍和医药技术有限公司 Medicine compounds for pulmonary and rheumatic heart disease and preparing method thereof
CN102058757A (en) * 2010-11-25 2011-05-18 代龙 Traditional Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961928A (en) * 2005-11-10 2007-05-16 杨文龙 Blood circulation-activating stasis-removing medicament for treating blood stasis syndrome and preparation process thereof
CN101229267A (en) * 2008-01-14 2008-07-30 北京中科雍和医药技术有限公司 Medicine compounds for pulmonary and rheumatic heart disease and preparing method thereof
CN102058757A (en) * 2010-11-25 2011-05-18 代龙 Traditional Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘继青: "《中医常用方剂汇编》", 31 May 2014, 厦门大学出版社 *
张红星等: "《实用中西医结合老年病学》", 30 April 2007, 中国医药科技出版社 *

Similar Documents

Publication Publication Date Title
CN101804166B (en) Traditional Chinese medicine composition for treating dermatitis and eczema of infants
CN103169903B (en) Traditional Chinese medicine preparation for treating child bronchitis and preparation method thereof
CN103432559B (en) Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof
CN103041256B (en) Chinese herb preparation for curing recurrent respiratory tract infection of children
CN103041257B (en) Chinese materia medica preparation for curing high fever and respiratory tract infection of children
CN104906507A (en) Traditional Chinese medicine combination for lowering blood pressure and toning physical fitness
CN102552748A (en) Traditional Chinese medicine capable of maintaining beauty and keeping young
CN103041255B (en) Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children
CN104998197A (en) Traditional Chinese medicine composition for treating liver cancer
CN104274592A (en) Medicine for treating tinea versicolor
CN107213360A (en) A kind of Chinese medicine composition for treating heavy myasthenia
CN106039240A (en) Traditional Chinese medicine composition for treating mammary fibroadenoma
CN103690869B (en) Chinese medicine for the treatment of irritable bowel syndrome and preparation method thereof
CN102038889B (en) Traditional Chinese medicament for treating rheumatic heart disease
CN104524422A (en) Pill for treating gynecomastia and preparation method thereof
CN103212026A (en) Traditional Chinese medicine for treating cholelithiasis as well as preparation method and taking method thereof
CN104491194A (en) Medicine for treating cardiopulmonary stasis blocking type rheumatic heart disease and preparation method of medicine
CN103041258B (en) Chinese materia medica preparation for curing respiratory tract infection with poor appetite of children
CN106692858A (en) Medicine for treating threatened abortion and preparation method of medicine
CN105709176A (en) Traditional Chinese medicine composition for treating heart blood stasis type palpitation and preparation method thereof
CN105687362A (en) Blood-activating dysentery-relieving pill for treating chronic dysentery
CN104257860A (en) Drug for treating neurodermatitis
CN104826068A (en) Medicine for expelling wind and eliminating dampness and preparation method of medicine
CN104189507A (en) Traditional Chinese medicine preparation for treating female feverishness in palms and soles
CN104225506A (en) Medicinal preparation for treating thrombocytopenia after chemotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408

RJ01 Rejection of invention patent application after publication